Reason for request

Re-assessment of the actual benefit in accordance with article R.163-21 of the Social Security Code. This re-assessment follows a pharmacovigilance alert relating to an increased mortality observed in the course of clinical studies carried out both in indications validated and not validated by the Marketing Authorisation (MA).


Clinical Benefit


The actual benefit of the propriety medicinal product remains substantial only in restricted clinical situations, complicated clinical forms of skin and soft tissue infections and intra-abdominal infections involving bacteria sensitive to tigecycline and when alternative treatments are considered inappropriate.

Contact Us

Évaluation des médicaments